Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheena McCormack

Showing results (21-30 of 117) with videos related to

Pageof 12
Sort By:
The Lancet. HIV|June 13, 2018
The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agentsDavid T Dunn, David V Glidden, Oliver T Stirrup, et al.
AIDS Care|September 14, 2012
How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African communityMitzy Gafos, Misiwe A Mzimela, Hlengiwe B Ndlovu, et al.
Sexual Health|November 30, 2018
Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and examples of successful health service models of PrEP implementationIryna B Zablotska, Jared M Baeten, Nittaya Phanuphak, et al.
The American Journal of Bioethics : AJOB|October 18, 2012
Ethics, justice and community participation in the Microbicides Development Programme (MDP) Phase III trial in Mwanza, TanzaniaAndrew Vallely, Shelley Lees, Charles Shagi, et al.
Trials|October 29, 2009
Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV preventionAndrew Nunn, Sheena McCormack, Angela M Crook, et al.
Clinical Trials (London, England)|November 9, 2011
The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trialJulie M Bakobaki, Mary Rauchenberger, Nicola Joffe, et al.
Clinical Trials (London, England)|January 23, 2025
Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trialSheila Kansiime, Christian Holm Hansen, Eugene Ruzagira, et al.
Sexually Transmitted Infections|October 25, 2017
How many MSM are taking PrEP: a service evaluationGary George Whitlock, Ashley Douglas, Sonia Adesara, et al.
AIDS (London, England)|May 25, 2016
Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbiditiesNicolò Girometti, Rachael Jones, Jeremy Levy, et al.
AIDS and Behavior|December 17, 2013
The implications of post-coital intravaginal cleansing for the introduction of vaginal microbicides in South AfricaMitzy Gafos, Robert Pool, Misiwe Adelaide Mzimela, et al.
Pageof 12

Showing results (21-30 of 117) with videos related to

Sort By:
Pageof 12
The Lancet. HIV|June 13, 2018
The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agentsDavid T Dunn, David V Glidden, Oliver T Stirrup, et al.
AIDS Care|September 14, 2012
How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African communityMitzy Gafos, Misiwe A Mzimela, Hlengiwe B Ndlovu, et al.
Sexual Health|November 30, 2018
Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and examples of successful health service models of PrEP implementationIryna B Zablotska, Jared M Baeten, Nittaya Phanuphak, et al.
The American Journal of Bioethics : AJOB|October 18, 2012
Ethics, justice and community participation in the Microbicides Development Programme (MDP) Phase III trial in Mwanza, TanzaniaAndrew Vallely, Shelley Lees, Charles Shagi, et al.
Trials|October 29, 2009
Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV preventionAndrew Nunn, Sheena McCormack, Angela M Crook, et al.
Clinical Trials (London, England)|November 9, 2011
The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trialJulie M Bakobaki, Mary Rauchenberger, Nicola Joffe, et al.
Clinical Trials (London, England)|January 23, 2025
Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trialSheila Kansiime, Christian Holm Hansen, Eugene Ruzagira, et al.
Sexually Transmitted Infections|October 25, 2017
How many MSM are taking PrEP: a service evaluationGary George Whitlock, Ashley Douglas, Sonia Adesara, et al.
AIDS (London, England)|May 25, 2016
Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbiditiesNicolò Girometti, Rachael Jones, Jeremy Levy, et al.
AIDS and Behavior|December 17, 2013
The implications of post-coital intravaginal cleansing for the introduction of vaginal microbicides in South AfricaMitzy Gafos, Robert Pool, Misiwe Adelaide Mzimela, et al.
Pageof 12